Organization (Industry)
GAIA, INC
ClinicalTrials.gov lists GAIA, INC as lead sponsor of 20 trials. It has 3 active development programs.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Gaia, Inc., via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers GAIA, INC: 20 lead-sponsored trials and 2 legal-entity registrations.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (22)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 3 |
| Diabetes Mellitus, Type 2 | 3 |
| Multiple Sclerosis | 3 |
| Attention Deficit Disorder with Hyperactivity | 2 |
| Borderline Personality Disorder | 2 |
Showing 5 of 22 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 8 |
| 2023 | 6 |
| 2022 | 2 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 1 |
| 2016 | 1 |
Showing 10 of 11 years.
Prediction, not a registry value: median of 18 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 11 months across 14 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (3)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Treatment As Usual | Diabetes Mellitus | Not reported | 1 |
| Treatment As Usual | Diabetes Mellitus, Type 2 | Not reported | 1 |
| Treatment As Usual | Multiple Sclerosis | Not reported | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 71% hit target (n=14) | 31% on time (n=13) |
Journals published in (33)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| BMJ open | 3 |
| Multiple sclerosis (Houndmills, Basingstoke, England) | 3 |
| Trials | 3 |
| Cognitive behaviour therapy | 2 |
| Acta psychiatrica Scandinavica | 1 |
Showing 5 of 33 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 2 | 0 | 2020-05-19 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 98,954,000 | -4,494,000 | not reported |
| 2024 | 89,296,000 | -5,233,000 | not reported |
| 2023 | 80,423,000 | -5,595,000 | not reported |
| 2022 | 82,035,000 | -3,595,000 | not reported |
| 2021 | 79,573,000 | 3,731,000 | not reported |
| 2020 | 66,827,000 | 519,000 | not reported |
| 2019 | 53,979,000 | -18,150,000 | not reported |
| 2018 | 41,997,000 | -33,793,000 | not reported |
| 2017 | 28,290,000 | -23,272,000 | not reported |
| 2016 | 17,247,000 | 87,066,000 | not reported |
Showing 10 of 11 fiscal years.
Financing and grant events (17)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-02-05 | Other financing | not disclosed | Edgar offerings |
| 2025-07-29 | Debt financing | not disclosed | Sec extracted |
| 2025-02-07 | Public offering | 7,200,000 | Sec extracted |
| 2025-02-06 | Other financing | not disclosed | Edgar offerings |
| 2025-02-05 | Other financing | not disclosed | Edgar offerings |
Showing 5 of 17 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 1 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (14)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University Medical Center Goettingen | Co sponsors trial with | 2 |
| University Hospital Schleswig-Holstein | Co sponsors trial with | 2 |
| University of Cologne | Co sponsors trial with | 2 |
| Universität Hamburg | Co sponsors trial with | 2 |
| Heinrich-Heine University, Duesseldorf | Co sponsors trial with | 2 |
Showing 5 of 14 relationships.
Latest dated events (47)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-05 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-07-29 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-02-13 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-02-07 | Public offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 47 events.
Biomarker capability evidence (7)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| BCL2L10 | Trial sponsor | Named in trial inclusion criteria |
| CYP19A1 | Trial collaborator | Named in trial inclusion criteria |
| BCL2L10 | Trial sponsor | Mentioned in trial text |
| CYP19A1 | Trial collaborator | Mentioned in trial text |
| CYP19A1 | Trial collaborator | Mentioned in trial text |
Showing 5 of 7 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, approved assets, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.